Research programme: Alzheimer's disease therapeutics - AZTherapies

Drug Profile

Research programme: Alzheimer's disease therapeutics - AZTherapies

Alternative Names: ALZT-OP2; ALZT-Patch; ALZT-QoL

Latest Information Update: 27 May 2014

Price : $50

At a glance

  • Originator AZTherapies
  • Class Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Amyloid beta-protein inhibitors; Inflammation mediator inhibitors; Synuclein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Alzheimer's disease

Most Recent Events

  • 01 May 2014 Early research in Alzheimer's disease in USA (Inhalation)
  • 01 May 2014 Early research in Alzheimer's disease in USA (Transdermal)
  • 01 May 2014 Preclinical trials in Alzheimer's disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top